8th Treg-Directed Therapies Summit
March 24 – 26, 2026 | Boston, MA
Advancing modulator and Treg cell therapies to accelerate clinical translation, redefine immune tolerance, and deliver transformative treatments for autoimmune, inflammatory, and neurodegenerative diseases.
With growing momentum—highlighted by Nobel recognition, Nektar Therapeutics’ clinical progress, and ORCA-T’s potential as the first FDA-approved Treg therapy—Treg therapeutics are entering a pivotal era. The 8th Treg-Directed Therapies Summit gathers leading experts from Quell Therapeutics, Nektar, Sanofi, Yale, and others to address challenges in cell targeting, mechanisms of action, cytokine biology, indication prioritization, GMP and regulatory pathways, clinical trial design, and validated efficacy endpoints to advance Treg therapies toward broader clinical success.
Neuroscience Innovation Pharma Partnering Summit
April 28-29 , 2026 | Boston, MA
Advance collaboration and partnerships across neurology and psychiatry to de-risk development, validate emerging technologies, and achieve improved biodistribution of safe, effective molecules targeting the central nervous system.
The Neuroscience Innovation Pharma Partnering Summit brings together pharma, biotech and investor leaders to accelerate collaboration in neurology and psychiatry. With a focus on CNS drug delivery, modality innovation and efficient partnering, the summit enables pre-scheduled one-on-one meetings and curated networking — including speed-matchmaking — to validate technologies, de-risk pipelines, and secure strategic alliances. It’s a targeted, high-impact forum to help safe, effective CNS therapies reach patients faster.
Search